Kyverna Therapeutics (KYTX) Profit After Tax (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Profit After Tax data on file, last reported at -$39.9 million in Q1 2026.

• Quarterly Profit After Tax rose 10.77% year-over-year to -$39.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$156.6 million (down 7.62% YoY) and the FY2025 annual result came in at -$161.3 million, down 26.51% from the prior year.
• Profit After Tax declined to -$39.9 million in Q1 2026, from -$37.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $5000.0 in Q3 2023 to a low of -$60.4 million in Q4 2023.
• A 4-year average of -$31.8 million and a median of -$36.8 million in 2025 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 37.64% in 2024, down 686140.0% in 2024.
• Tracing KYTX's Profit After Tax over 4 years: stood at -$60.4 million in 2023, then jumped by 37.64% to -$37.7 million in 2024, then dropped by 0.37% to -$37.8 million in 2025, then slipped by 5.61% to -$39.9 million in 2026.
• The last three Profit After Tax figures came in at -$39.9 million (Q1 2026), -$37.8 million (Q4 2025), and -$36.8 million (Q3 2025), per Business Quant data.